Compare Devon Energy Corp (DVN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Devon Energy Corp trades at $44.87 (market cap $49.94B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Devon Energy Corp pays a 2.82% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Devon Energy Corp nearer its low. Which is the better fit depends on your goals.
| DVN | XBI | |
|---|---|---|
Market Cap | $49.94B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $52.07 | $164.28 |
52-Week Low | $31.74 | $86.92 |
Enterprise Value | $60.68B | — |
Dividend Yield | 2.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $44.9, down 1.01% today, with a bullish technical signal and strong Q2 2026 earnings beat. The company reported EPS of $1.57 versus $1.40 expected, driven by merger synergies and higher oil prices. Valuation remains attractive with a P/E of 9.87 and P/S of 1.62. Recent news highlights a 33% dividend increase and $1.25 billion debt repayment, reinforcing financial health.
The outlook is positive given robust free cash flow, debt reduction targets, and analyst consensus price target of $61.91 implying 38% upside. Key risks include oil price volatility and integration challenges from the Coterra merger. Institutional sentiment is strongly bullish with 71% buy ratings, supporting a favorable risk-reward profile for long-term investors.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
